New board members were selected at the 15th general shareholders meeting, and the board members appointed Kiichi Adachi as new President and CEO, and Kunio Iwatani as Chairman.
December 5, 2016
Kringle Pharma successfully raised 610 milion JPY to accelerate the clinical development of recombinant human HGF. （252KB）
September 24, 2016
Kringle Pharma's project entitled 'Recombinant human HGF for the treatment of acute spinal cord injury' was accepted by Japan Agency for Medical Research and Development, AMED, as its Drug Discovery Support Promotion Project.
May 13, 2016
An investigator-initiated Phase II clinical trial of recombinant human HGF starts at the Tohoku and Osaka University Hospitals for the treatment of
amyotrophic lateral sclerosis (ALS).
March 11, 2015
Kringle Pharma completed Phase I clinical trial of recombinant human HGF for amyotrophic lateral sclerosis (ALS). Primary objectives of the trial, the safety and pharmacokinetics of the HGF dosing, were successfully evaluated.